Evolvere BioSciences
Making Next-Generation Antibiotics that Outpace Bacterial Evolution
About
🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩⚕️. We are a team of biochemists and evolutionary biologists who met at the University of Oxford.
Founders
- Adam Winnifrith
- Piotr Jedryszek
- Weronika Slesak
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Evolvere BioSciences.
See family office activity